Marshall Wace
ALGS icon

Marshall Wace’s Aligos Therapeutics ALGS Stock Holding History

Marshall Wace’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42M Sell
246,579
-20,556
-8% -$127K ﹤0.01% 2031
2026
Q1 		$1.98M Sell
267,135
-1,529
-0.6% -$11.6K ﹤0.01% 1792
2025
Q4 		$2.5M Buy
+268,664
New +$2.53M ﹤0.01% 1469
2023
Q2 		– Sell
-4,344
Closed -$94.5K – 2417
2023
Q1 		$94.5K Buy
+4,344
New +$166K ﹤0.01% 2503

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's ALGS Position: Q2 2026 in Review

Marshall Wace reduced its Aligos Therapeutics (ALGS) stake by 7.7% in Q2 2026, selling an estimated $127K and leaving 246,579 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2031.

Marshall Wace first reported a position in ALGS in Q1 2023 and has held it in 4 quarters since. The position peaked at $2.5M in Q4 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Marshall Wace held 246,579 shares of Aligos Therapeutics worth $1.42M as of Q2 2026.
  • Marshall Wace sold 20,556 Aligos Therapeutics shares in Q2 2026, an estimated $127K.
  • Aligos Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2031 holding.
  • Marshall Wace first reported a position in Aligos Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Marshall Wace's Aligos Therapeutics position peaked at $2.5M in Q4 2025.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.